Skip to content

Author

J. McMurray

We have 8 of 275 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Lung ultrasound in ambulatory adults with HFpEF: Association between pulmonary congestion and one-year outcomes

Early detection of congestion among adults with heart failure and preserved ejection fraction (HFpEF) is critical to optimize therapy prior to overt decompensation, yet traditional tools are insensitive. We sought to examine the association between B-lines on lung ultrasound (LUS) in ambulatory adults with HFpEF...

Elke Platz, K. McDowell, Deepak K. Gupta et al. · 0 citations
Nov 2026

Ventricular arrhythmia-heart failure interaction and mortality in ICD recipients after myocardial infarction.

In ICD recipients with persistent LV dysfunction following MI, VA and HF events are bidirectionally associated and independently associated with mortality and the VA-HF association was strongest for shock-treated arrhythmias.

Matthieu Echivard, J. Sellal, J. McMurray et al. · 0 citations
Open access Oct 2026

NT-proBNP and Clinical Outcomes in Patients With HFrEF According to Atrial Fibrillation: Insights From QUEST.

BACKGROUND The Chinese traditional medicine qiliqiangxin (QLQX) improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF) when added to guideline-directed medical therapy. OBJECTIVES This post hoc analysis of the QUEST (Qiliqiangxin in Heart Failure: Assessment of Reduction in Mortality)...

L. Shen, Jun-Ru Li, I. Cheang et al. · 0 citations
Open access Oct 2026

Effect of traditional Chinese medicine Qiliqiangxin in patients With HFrEF treated with sacubitril/valsartan: the QUEST trial

Heart failure with reduced ejection fraction (HFrEF) remains a leading cause of cardiovascular morbidity and mortality globally, despite recent advances in therapy, and new treatments that have added benefit are still needed. Qiliqiangxin (QLQX), a Traditional Chinese Medicine (TCM) formulation, has demonstrated...

I. Cheang, X. Zhu, L. Shen et al. · 0 citations
Open access Aug 2026

HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Insights From the FINEARTS-HF Trial.

BACKGROUND The HFpEF-ABA score is a simple diagnostic tool developed to estimate the probability of heart failure with preserved ejection fraction (HFpEF) using age, body mass index, and history of atrial fibrillation. OBJECTIVES This study aims to evaluate the HFpEF-ABA score in patients with confirmed heart failure...

R. Ono, K. Docherty, A. Henderson et al. · 0 citations
Open access Aug 2026

Personalized evaluation of NT-proBNP and clinical characteristics in suspected heart failure: the PRECISE-HF study.

BACKGROUND AND AIMS N-terminal pro-B-type natriuretic peptide (NT-proBNP) is recommended to guide echocardiography referral in community-based patients with suspected heart failure (HF), but diagnostic performance is influenced by individual characteristics including age, ethnicity, kidney function, cardiac rhythm, and...

K. Docherty, B. Heywood, L. Anderson et al. · 0 citations
Open access Aug 2026

Short-term effects of combinations of heart failure therapies on blood pressure, kidney function and serum potassium.

A prediction model is developed to estimate the short-term treatment effects of combination medical therapy on systolic blood pressure (SBP), diastolic BP, estimated glomerular filtration rate (eGFR) and serum potassium and individualized estimates of the expected treatment effect are provided.

Nelson Wang, B. Claggett, M. Pfeffer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.